01896 Overview

Stock Ratings and Price Targets: Various companies including Alibaba, Baidu, and JD.com received "Buy" ratings with specific price targets, while others like Meituan and Tencent were rated "Neutral" or faced declines in stock prices.

Short Selling Data: Significant short selling activity was noted for several stocks, with Meituan and Kuaishou showing high short selling ratios of 20.96% and 19.47%, respectively.

Market Movements: The stock prices of companies like Meituan and Tencent experienced declines, while others like Yixin and IGG saw slight increases.

Analyst Insights: Daiwa maintained a "Buy" rating on Meituan, indicating expectations of widening losses for its Keeta service in the upcoming year.

Market Performance: The HSI rose by 209 points (0.8%) to 26,068, with the HSCEI and HSTECH also showing gains, while total market turnover reached HKD114.975 billion.

Tech Stock Movements: Meituan-W fell 1.5% after reporting a loss, while Alibaba and Netease saw increases of 3.3% and 2.2%, respectively, amidst varying short selling ratios across tech stocks.

Consumer and Auto Stocks: Consumer stocks like CTG Duty-Free and Tongcheng Travel surged by 7.3% and 6.2%, while some auto stocks like Chery Auto and BYD Company also experienced gains, despite declines in others like Li Auto.

Handset Component Stocks: Stocks in the handset component sector, including Sunny Optical and Lens, saw significant increases of over 6%, reflecting positive market sentiment in that segment.

Box Office Success: Disney's "Zootopia 2" has achieved a box office of USD 272 million in China, making it the second highest foreign film premiere in the country, following "Avengers: Endgame."

Future Projections: MAOYAN ENT forecasts that "Zootopia 2" could potentially reach RMB 4.26 billion in China, which may allow it to match the earnings of "Avengers: Endgame."

Geopolitical Tensions: Rising tensions between China and Japan have led to the delay of two Japanese films, "Crayon Shin-chan: The Hot Kasukabe Dancers" and "Cells at Work!", as reported by Citi.

Limited Box Office Impact: Despite the delays, Japanese films accounted for only 5% of China's box office last year, suggesting minimal actual impact on overall box office revenue.

Market Sentiment Concerns: The delays may affect market sentiment, particularly regarding investor worries about MAOYAN ENT's potential suspension of the film "Demon Slayer" if tensions worsen.

Target Prices Set: Citi has established target prices for DAMAI ENT at HKD1.4 and MAOYAN ENT at HKD9.3, indicating a cautious outlook amidst the geopolitical climate.

Market Performance: The Hang Seng Index (HSI) fell 213 points (0.8%) to 26,359, with significant declines in tech stocks like Alibaba and Tencent, both down around 0.6%.

Retail Sales and Economic Indicators: China's retail sales growth for October was reported at 2.9%, slightly below the previous month's 3.0%, while the Producer Price Index (PPI) showed a year-on-year decline of -2.1%.

Travel Advisory Impact: China's Ministry of Culture and Tourism issued a travel advisory against visiting Japan, negatively affecting tourism-related stocks such as Tongcheng Travel and Trip.com, which saw declines of 2.2% and 4.9%, respectively.

Pharmaceutical Sector Weakness: The pharmaceutical sector experienced significant losses, with companies like Pharmaron and CansinoBio dropping 5.3% and 3.9%, respectively, amid a broader trend of declining stock prices in the industry.

Citi Research Report: Citi Research has initiated a 30-day positive catalyst watch on MAOYAN ENT (01896.HK) due to the upcoming release of the animated movie Demon Slayer on November 14, which it will distribute.

Box Office Performance: The film has already achieved significant global success, ranking fifth worldwide with over US$677 million and becoming the top international movie in North America.

Popularity Metrics: The announcement of Demon Slayer has led to a surge in interest, with Maoyan Pro recording over 400,000 'to-watch' clicks in just one day.

Investment Outlook: Citi Research maintains a Buy rating for MAOYAN ENT, setting a target price of $9.3 based on a 14x adjusted EPS for 2026, anticipating that box office success during the New Year holiday will positively impact the company.